Innocoll Holdings, a specialty pharma company wholly-owned by Gurnet Point Capital, a private investment firm focused on health care, has named Louis Pascarella its new chief executive.
Mr Pascarella will retain his current role of president and is succeeding Rich Fante, who is stepping down after a successful tenure as chief executive. He has agreed to serve as an adviser to Innocoll’s board for at least the next year to ensure a smooth transition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze